Physicians and researchers at the Aflac Cancer Center are conducting a series of clinical studies and trials to improve care for our young patients, in addition to adults, which include:
A Phase 3, double-blind, randomized, placebo-controlled, multicenter study of GBT440 Administered Orally to Patients with Sickle Cell Disease
- The purpose of this study is to compare a new oral drug, GBT440, with a placebo in a large number of subjects with sickle cell disease. The key purpose of this study is to establish the benefit and safety of GBT440.
A Pilot Study of Hydroxyurea Management in Kids: Intensive Versus Stable Dosage Strategies (HUGKISS)
- The HUGKISS trial addresses if an accelerated dosing of hydroxyurea safely results in improved blood and urine laboratory results, as well as reduced sickle cell related complications, compared to a fixed dose of hydroxyurea.
Effects of Sickle Hemoglobin on Brain Perfusion (Sickle-HOPE)
- The goal of this study is to develop and evaluate feasibility of a novel functional imaging protocol that maps cerebral blood flow and oxygen delivery for children at risk for stroke due to sickle hemoglobin.
A Phase IIA, Open-label, PK, Safety, Tolerability and Treatment Effect of GBT440 in Children with SCD (GBT440-007)
- The purpose of this study is to compare a new oral drug, GBT440, with a placebo in a large number of subjects with sickle cell disease. GBT440 may help slow down the destruction of red blood cells and improve the health of blood vessels in the brain.